Search-Borryen Pharmaceutical | Precision drug analysis

Search

Home page

Product

News

Based on your search criteria, we have found the following for you:

Bryheng Peptide Analysis Platform! LC-MS/MS technology precisely powers GLP-1 drug development, driving new breakthroughs in metabolic therapies.

In the fields of diabetes and obesity treatment, GLP-1 receptor agonists have undoubtedly emerged as a shining star. Drugs such as semaglutide, liraglutide, exenatide, and tirzepatide are reshaping the lives of hundreds of millions of patients worldwide, thanks to their remarkable blood sugar-lowering and weight-loss effects.

Sep 01,2025

Bryheng Peptide Analysis Platform! LC-MS/MS technology precisely powers GLP-1 drug development, driving new breakthroughs in metabolic therapies.

Breaking Through Challenges in Insulin Compound Detection: The Success Story of BoreiHeng Pharmaceutical Technology

In the field of diabetes drug development and treatment monitoring, accurately measuring the blood concentrations of insulin and its analogs—such as human insulin, aspart insulin, glargine insulin, and degludec insulin—presents a central challenge. These compounds, characterized by their large molecular weights, significant endogenous interference, and extremely low exposure levels, place nearly exacting demands on analytical methods. Thanks to its deep-rooted technological expertise, Wuhan Brightrun Pharmaceutical Technology Co., Ltd. has successfully overcome these industry hurdles.

Jul 23,2025

Breaking Through Challenges in Insulin Compound Detection: The Success Story of BoreiHeng Pharmaceutical Technology

Double Celebration Shines Bright | Berriheng Warmly Reunites, Embarking Together on a New Journey of Growth—Employee Recognition Ceremony & Birthday Party Held as Scheduled

At the event's outset, the company proudly honored its top-performing employees of the quarter by presenting them with certificates of recognition and bespoke awards, celebrating their unwavering dedication to excellence in the biopharmaceutical testing field. Whether it was the technical experts who meticulously manage experimental data or the skilled managers who seamlessly coordinate projects, each individual exemplified the company’s core value of "Professionalism Drives Value" through their relentless pursuit of precision and innovation. Their exemplary efforts have become the benchmark for the entire team to strive toward. The room erupted in enthusiastic applause—both a heartfelt acknowledgment of these role models and a powerful testament to Berriheng employees' collective determination to continuously elevate themselves to meet the highest standards.

May 30,2025

Double Celebration Shines Bright | Berriheng Warmly Reunites, Embarking Together on a New Journey of Growth—Employee Recognition Ceremony & Birthday Party Held as Scheduled

Boruiheng Joins Donghu Biopharmaceutical Association: Partnering with Optics Valley’s "Pharmaceutical Valley" to Jointly Build an Innovative Ecosystem

In February 2025, Wuhan Buruiheng Pharmaceutical Technology Co., Ltd. officially became a member unit of the Wuhan East Lake National Independent Innovation Demonstration Zone Biomedical Industry Association, marking the company's deep integration into the innovation ecosystem of Optics Valley Bio-City and launching a new journey of collaborative industry-academia-research development.

May 29,2025

Boruiheng Joins Donghu Biopharmaceutical Association: Partnering with Optics Valley’s "Pharmaceutical Valley" to Jointly Build an Innovative Ecosystem

Breakthrough! Wuhan Buruiheng Pharmaceutical Technology Co., Ltd. Launches a New Era in Bio-Detection with Estrogen/Estrone Testing

In clinical diagnostics and medical research, precise measurement of estradiol and estrone levels is critically important. Estradiol plays a key role in female reproduction and male metabolism, while estrone is involved in endocrine regulation. Abnormal fluctuations in the levels of these two hormones have been linked to various diseases. However, detecting them poses significant challenges: as they are naturally occurring endogenous substances, conventional methods cannot be used to create reliable standard curves. Additionally, the commonly employed surrogate matrix approach is often cumbersome and complex to implement. Moreover, steroids in biological matrices exist in both bound and unbound forms, and without proper reference standards, enzymatic hydrolysis-based quantitative analysis requires carefully optimized conditions. On top of this, current detection methods struggle to achieve the ultra-low quantification limits required—often down to the picogram level—while also demanding relatively large sample volumes, which can limit the analysis of precious or limited samples. Fortunately, our company has just announced exciting progress in the field of bioanalysis, offering promising solutions that could overcome these longstanding challenges.

May 15,2025

Breakthrough! Wuhan Buruiheng Pharmaceutical Technology Co., Ltd. Launches a New Era in Bio-Detection with Estrogen/Estrone Testing

Good News | Wuhan Beruiheng BSL-2 Laboratory Successfully Registered!

Recently, Wuhan Buruiheng Pharmaceutical Technology Co., Ltd. (hereinafter referred to as Wuhan Buruiheng) successfully completed the on-site audit of its laboratory facilities and operational system conducted by an expert team from the Wuhan Municipal Health Commission, smoothly obtaining Level 2 Biosafety (BSL-2, also known as P2) laboratory registration under.Record number: E Health Safety BSL-2 [2023] 01-14-021

Oct 08,2023

Good News | Wuhan Beruiheng BSL-2 Laboratory Successfully Registered!

Beriheng Project Experience and Analysis Methodology Catalog (as of June 2023)

As of June 2023, Berryheng has been approved for 33 projects, verified 20 projects, and exempted from verification in 20 projects. For details, please see the chart below:

Jul 18,2023

Beriheng Project Experience and Analysis Methodology Catalog (as of June 2023)

Great news! Fast-rising Beriheng has been named a 2022 "Optics Valley Gazelle" company!

On December 5, Wuhan Boreiheng Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Boreiheng") received the prestigious "Optics Valley Gazelle" Corporate Plaque for 2022, awarded by the Wuhan East Lake High-tech Development Zone. Recognized as a high-growth enterprise with strong technological capabilities, significant growth potential, and mastery of critical core technologies, Boreiheng has been proudly named among China's Optics Valley Gazelle companies.

Dec 08,2022

Great news! Fast-rising Beriheng has been named a 2022 "Optics Valley Gazelle" company!

Good News | Wuhan Beriheng Pharmaceutical Technology Co., Ltd. has been recognized as a member of the seventh batch of "Specialized, Fine, and New" SMEs in Hubei Province!

On May 8, 2025, the Hubei Provincial Department of Economy and Information Technology officially announced the seventh batch of provincial-level specialized, sophisticated, and innovative (SSM) SMEs. Wuhan Boreiheng Pharmaceutical Technology Co., Ltd. successfully earned the title of "Hubei Provincial SSM Enterprise," thanks to its strong advantages in specialization, precision, and distinctive development within the pharmaceutical technology sector—and after passing rigorous multi-level evaluations! This achievement marks another significant milestone for the company, following its recent recognition as a National High-Tech Enterprise, further solidifying its leadership in innovation capability, market competitiveness, and industry influence.

May 09,2022

Good News | Wuhan Beriheng Pharmaceutical Technology Co., Ltd. has been recognized as a member of the seventh batch of "Specialized, Fine, and New" SMEs in Hubei Province!

Good News | Borei Heng Pharmaceutical Elected as a Member of the CRO Division of the China Association for Pharmaceutical Quality Management

On September 14, 2024, the third meeting of the Clinical Trial Contract Research Organization Branch (hereafter referred to as the CRO Branch) of the China Association for Pharmaceutical Quality Management was successfully held in Wuhan. Attendees included Ye Xiaoping, Chairman of Hangzhou Tigermed Co., Ltd. and Chairperson-elect of the CRO Branch; Wu Jie, Chairman of Northway (Beijing) Pharmaceutical Technology Co., Ltd.; along with nearly 60 representatives from 36 member organizations. The meeting was chaired by Wang Wei, Senior Vice President of Northway (Beijing) Pharmaceutical Technology Co., Ltd. and Secretary-General of the CRO Branch.

Nov 12,2021

Good News | Borei Heng Pharmaceutical Elected as a Member of the CRO Division of the China Association for Pharmaceutical Quality Management

Good News | Berriheng Helps Yueyang Xinhua Dafu's Bisoprolol Fumarate Tablets Pass Generic Drug Consistency Evaluation!

In May 2020, Yueyang Xinhua Da Pharmaceutical Co., Ltd. (hereinafter referred to as "Yueyang Xinhua Da Pharmaceutical") received the "Drug Supplementary Application Approval" for Bisoprolol Fumarate Tablets (5mg per tablet, Acceptance No.: CYHB1950120), issued and approved by the National Medical Products Administration. The drug has successfully passed the evaluation of quality and therapeutic equivalence for generic drugs.

Jun 30,2020

Good News | Berriheng Helps Yueyang Xinhua Dafu's Bisoprolol Fumarate Tablets Pass Generic Drug Consistency Evaluation!

Great News | Borei Heng Pharmaceutical Enters the National High-Tech Enterprise Ranking!

As one of the nation’s highest honors for high-tech enterprises, qualification recognition requires meeting several key criteria simultaneously: the core technology must possess independent intellectual property rights, the products or services must fall within the scope of high-tech fields, the company must have a significant proportion of science and technology professionals, demonstrate robust research and development expenditures, showcase strong innovation capabilities, effectively convert scientific and technological achievements into market value, and meet favorable growth indicators.

May 10,2020

Great News | Borei Heng Pharmaceutical Enters the National High-Tech Enterprise Ranking!

Wuhan Brightrun Pharmaceutical Technology Co., Ltd.

Mobile: 8619913181561 (Ms. Wang)

Email: bd@whbrh.cn

Address: Building B4, Optics Valley Bio-city, 666 Gaoxin Avenue, Hongshan District, Wuhan City

WeChat

WhatsApp：8619913181561

E-mail：bd@whbrh.cn

Tel：8619913181561

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

required

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

analyze

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

Feature

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

advertise

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

武汉伯瑞恒医药科技有限公司